Skip to content

A randomized controlled study of Liuzijue for improving respiratory muscle dysfunction in chronic obstructive pulmonary disease

A randomized controlled study of Liuzijue for improving respiratory muscle dysfunction in chronic obstructive pulmonary disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107043
Enrollment
Unknown
Registered
2025-08-01
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

Interventions

Liuzijue Group:Conventional drug treatment combined with Liuzijue training

Sponsors

The First Affiliated Hospital of Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of stage II.-III. moderate-severe COPD disease, and in the stable period within 3 months before randomization; 2. Gender is not limited, between 40 and 80 years old; 3. Patients who voluntarily participate in the trial and cooperate with active and good compliance; 4. Patients who did not participate in regular activities of various exercises in the first six months of the trial (> 2 times a week, 50 min/time exercise)

Exclusion criteria

Exclusion criteria: 1. Patients under 40 years old and over 80 years old; 2. Diagnosed with COPD disease, but the patient is in the acute exacerbation stage and needs to be hospitalized or targeted drug treatment; 3. Patients with COPD combined with asthma, lung infection, tuberculosis, bronchiectasis, lung cancer and other respiratory diseases who are not suitable for rehabilitation exercise; 4. Patients with COPD combined with serious major diseases of the heart, brain, blood vessels, liver, kidney, digestion, endocrine, nerves and other systems; 5. Have mental or unconscious disorders, causing the patient to be unable to cooperate with treatment and evaluation; 6. Subjects who are participating in other clinical intervention or drug trials at the same time; 7. Patients with musculoskeletal diseases or open injuries who are not suitable for limb muscle strength assessment

Design outcomes

Primary

MeasureTime frame
Ratio of forced expiratory volume in the first second (FEV1) to forced vital capacity (FVC).;The six-minute walk test;Respiratory muscle surface EMG signal ;

Secondary

MeasureTime frame
St George's Respiratory Questionnaire;Core isokinetic muscle strength test;Kinematic detection of respiratory chain;

Countries

China

Contacts

Public ContactFanfu Fang

The First Affiliated Hospital of Naval Medical University

fangfanfu@126.com+86 158 0071 9913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026